CERO News & Events

CERo Therapeutics provides an update through the letter to stockholders and stakeholders from CEO Chris Ehrlich: "Following our recent Form 8-K filing confirming receipt of convertible debt funding to support current operations, we believe it is an appropriate time to provide an update on CERo Therapeutics' operational and scientific progress... During this period, we have progressed the development of our lead candidate, CER-1236, including observations consistent with an acceptable safety and tolerability profile to date, across multiple treated patients.. Notably, in the second patient treated in our ongoing Phase I study, we observed an interval of apparent disease stability during which the patient's disease progression and requirement for platelet transfusion support did not increase following multiple infusions of CER-1236... The emerging clinical observations provide an early signal that supports continued investigation of CER-1236. These data are helping guide the Company's ongoing development strategy, including exploration of dosing approaches and patient selection in future cohorts... We recently announced data from our ongoing CERTAIN-T Phase 1 clinical trial that reflects the Company's current development approach for our lead compound, CER-1236... Re-establishing our listing on a major exchange remains one of our key priorities. To that end, we have engaged with an investment bank to raise capital and pursue a strategy intended to support a potential relisting on the Nasdaq Capital Market... As recently disclosed, as we pursue new financing opportunities and seek to relist on Nasdaq, our lead investor continues to support CERo's operations through investments in convertible debt... We continue to engage in ongoing discussions with potential strategic partners following the most recent data readouts, as is regularly seen in the biotech industry. While these conversations are encouraging, they remain at an early stage and have not resulted in formal agreements... Pur take-home message is clear: CERo is operational, continuing to advance our clinical programs, and generally building momentum. We are committed to transparent communication, and we look forward to sharing the outcomes of each of our ongoing activities in the future. We thank you for your continued support and confidence in our novel approach to treatment and our leadership."

CERo Therapeutics Holdings (CERO) announces the appointment of Eric Francois to the Company's Board of Directors. Formerly, he served as CFO of SCYNEXIS (SCYX).

CERo Therapeutics announces a presentation highlighting data to date from the Company's Phase 1 clinical trial, called CERTAIN-T, of its lead compound, CER-1236. Reflective of the Company's recent clinical update, the data highlight results from the first cohort of the trial, featuring a positive safety and tolerability profile, and rapid in vivo cell expansion, with observed approximately 20-70-fold expansion, peaking between days 7-14, followed by prolonged persistence. The data presentation also includes outcomes from an index patient with acute myeloid leukemia, AML, that progressed from myelodysplastic syndrome, MDS, who received a total of four CER-1236 infusions over 5 months at the lowest dose level. Prior to treatment with CER-1236, the patient required frequent platelet transfusions, but after treatment he developed transfusion independence lasting over two months. The data are being presented at the Tandem Meeting of the American Society of Transplantation and Cellular Therapy, ASTCT, and the Center for International Blood and Marrow Transplant Research, CIBMTR, meeting in Salt Lake City, Utah, February 4-6, 2026.

CERo Therapeutics announces a key clinical update from the Company's ongoing CertainT-1 trial focused on patients with acute myeloid leukemia. Following completion of the dose-limiting toxicity observation period for the first cohort, investigators observed cell expansion with no CRS, ICANS, or treatment-related adverse events reported to date. Expansion was seen with or without lymphodepletion. Investigators gave four rounds of CER-1236 cells to the second patient enrolled, with myelodysplastic syndrome that progressed to AML with an inv3 chromosome translocation. A 61-day platelet transfusion-free interval was observed after CER-1236 treatment, exceeding a commonly referenced 8-week benchmark cited in clinical studies in the context of platelet transfusion independence. Transfusion independence ended following a subsequent round of lymphodepleting chemotherapy plus CER-1236 treatment.